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Introduction: Resistance to traditional antibiotics is an increasingly serious problem. Antimi-
crobial peptides (AMPs) have emerged as a new therapeutic class with great potential against 
infectious diseases, as they are less prone to induce resistance. Nanotechnology-based delivery 
strategies can improve the efficiency and stability of AMPs, particularly against proteolytic 
degradation. Lipid nanocapsules (LNCs) are a new generation of biomimetic nanocarriers and 
were used in this study to deliver peptides.
Methods: AMP-loaded reverse micelles (RM) were developed and incorpo rated into LNCs 
by the phase inversion process and the antimicrobial activity of the AMPs-loaded LNC was 
evaluated by the minimum inhibitory concentration method. We studied the activity of AMP 
solutions and AMP-loaded LNCs against Gram-positive and Gram-negative bacterial strains and 
then evaluated the encapsulation of a new cationic AMP called AP138. Finally, we analyzed the 
effect of enzymatic attack on AP138 and AP138-RM-LNCs after incubation with trypsin.
Results: AP138 was efficiently encapsulated in the LNCs (encapsulation efficiency = 97.8% 
at a drug loading of 0.151%), resulting in protection against degradation by proteases and the 
preservation of antimicrobial activity against Staphylococcus aureus, including methicillin-
resistant Staphylococcus aureus.
Conclusion: This study shows that RM-LNCs are an excellent candidate system to deliver AMPs.
Keywords: nanoparticles, nanomedicine, antibacterial, AMP, methicillin-resistant Staphylo-
coccus aureus, infection
Introduction
Bacterial infections constitute one of the most serious global public health threats 
in this century due to the rising incidence of nosocomial infections and the spread 
of multidrug-resistant bacteria. The first WHO global report on the surveillance of 
antimicrobial resistance, published in April 2014, collected data from national and 
international surveillance networks and shows the extent of this phenomenon in many 
parts of the world. A joint initiative of the WHO, Drugs for Neglected Diseases initia-
tive, and Global Antibiotic Research and Development Partnership encourages research 
and development through public–private partnerships. By 2023, the partnership aims 
to develop and deliver up to four new treatments through improvement of existing 
antibiotics and acceleration of the entry of new antibiotic drugs.1
Antimicrobial peptides (AMPs) are present in all organisms as a component of the 
innate immune system. AMPs inhibit a wide array of microbes by perturbation of the 
mitochondrial membrane ionic balance and membrane pore formation. Thus, AMPs 
have pleiotropic effects and immense potential in diverse medical fields.2 These peptides 
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represent a promising naturally derived new class of antibi-
otics.3 In various studies, they have shown activity against a 
wide variety of pathogens: Gram-positive and Gram-negative 
bacteria, including drug-resistant bacteria, fungi, viruses, and 
eukaryotic parasites. AMPs are generally composed of fewer 
than 50 amino acids, have a positive net charge, and are often 
amphiphilic.4 However, due to the inherent limitations of pep-
tides as drugs, efforts have focused on increasing their stability 
and bioavailability.5 One of the strategies to overcome these 
drawbacks is the incorporation of AMPs into novel formula-
tions, including nanocarriers, which are a promising peptide 
delivery system.6 For example, peptide-loaded nanoparticles 
increase the characteristics of tissue accumulation (increased 
tissue uptake and enhanced tissue permeation).7 Another 
advantage of the encapsulation of AMPs into nanocarriers is 
protection of the peptide against in vivo degradation, such as 
that by proteolytic enzymes.8 Lipid-based nanocarriers have 
generated increasing interest among nanoformulations because 
of their high degree of biocompatibility and versatility.9 Lange 
et al demonstrated the stability and efficacy of liposomes con-
taining the AMP CM3.10 Moreover, lipid-based drug delivery 
systems offer the potential to be AMP carriers due to the affin-
ity of the lipid components for the membrane.11
In this context, the original purpose of this study concerned 
the formulation of lipid nanoscale systems which combine all 
previously mentioned attributes. Lipid nanocapsules (LNCs) 
are a biomimetic drug delivery system composed of an oily 
core of medium triglycerides surrounded by a surfactant shell. 
These nanocapsules can be prepared without the use of toxic 
organic solvents by a low-energy process.12 They contain 
generally recognized as safe excipients and are compatible 
with scalable processes.13 The encapsulation of hydrophilic 
or hydrosoluble drugs into the lipid core was achieved by 
applying a simple idea that consists of incorporating a reverse 
micellar system to the LNC core. The micelle-loaded oil is 
incorporated into the oily continuous phase of the system, 
described above, at a temperature above the phase-inversion 
temperature (PIT). This process has been successfully applied 
to encapsulate dyes, such as fluorescein sodium salt,14 and 
the hydrophilic anticancer drugs doxorubicin hydrochloride15 
and erlotinib hydrochloride, belonging to the tyrosine kinase 
inhibitor family.16 It could also be successfully applied to pep-
tides. Moreover, the use of oleic Plurol® instead of Lipoid® 
in the formulation of the lipid core allows the entrapment of 
thermolabile molecules, such as plasmid DNA molecules, 
by decreasing the PIT.17
Plectasin is a cationic AMP that belongs to the class of 
defensins. It is produced by the saprophytic ascomycete 
Pseudoplectania nigrella.18,19 In contrast to other AMPs, 
which disrupt bacterial membranes, plectasin derivatives 
inhibit membrane biosynthesis by targeting the cellular 
precursor lipid II.18 The peptide AP138 is the product of an 
extensive lead optimization program based on a set of in 
silico generated plectasin variants.20 AP138 is active against 
Gram-positive bacteria, including Staphylococcus aureus 
(SA) and methicillin-resistant SA (MRSA), making it useful 
for the treatment of skin and soft-tissue infections.21 MRSA 
strains are highly resistant to many classes of antibiotics, 
including most β-lactams. Vancomycin is the drug of choice 
for the treatment of infections caused by MRSA; however, 
SA strains with elevated minimum inhibitory concentrations 
(MICs) against vancomycin are also emerging now.22 Thus, 
considerable effort has gone into developing alternatives to 
vancomycin for the treatment of MRSA.
In this context, our aim was to develop a new lipid-
based carrier for AMP delivery, evaluate its physicochemi-
cal properties, and predict its biopharmaceutical behavior. 
The antimicrobial activity of AMPs against SA and MRSA 
was tested in vitro using MIC and time-kill assays. Then, 
we analyzed the effect of enzymatic attack on AP138 and 
AP138-LNCs by trypsin. This work allowed us to explore 
the potential of LNCs for the delivery of AMPs to treat 
bacterial infections.
Materials and methods
Materials
The lipophilic Labrafac® WL 1349 (“caprylic–capric acid 
triglycerides”) and oleic Plurol® CC 497 (polyglyceryl-3 
dioleate; hydrophilic-lipophilic balance=3) were kindly 
provided by Gattefossé S.A. (Saint-Priest, France). Kolli-
phor® HS-15 (Sol), a mixture of free polyethylene glycol 660 
(~30%) and 12-hydroxystearate of polyethylene glycol 660 
(~70%), was provided by BASF (Ludwigshafen, Germany). 
Dioctyl sulfosuccinate sodium salt and trypsin were supplied 
by Sigma-Aldrich (St Louis, MO, USA). NaCl was purchased 
from Prolabo VWR International (Fontenay-sous-Bois, 
France). The AP138 AMP was synthesized and provided by 
PolyPeptide Laboratories (Limhamn, Sweden). HPLC-grade 
acetonitrile, methanol, and trifluoroacetic acid (TFA) were 
purchased from Fisher Bioblock (Illkirch, France). Deionized 
water was obtained from a Milli-Q plus system (Millipore, 
Paris, France).
Preparation of reverse micelles
Blank reverse micelles (RMs) were prepared by incubating 
dioctyl sulfosuccinate sodium salt for 3 hours at 45°C with 
Labrafac WL 1349 (1:10 w/w). AP138-RM was prepared by 
incubating AP138 (8 mg/g Labrafac WL 1349) with blank 
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RMs in the presence of water (4% w/w) for 2 hours at 45°C, 
after which excess AP138 (ie, non-solubilized remnants) was 
removed from the suspension by centrifugation at 4,000 rpm 
for 30 minutes at 20°C. We considered RMs to be formed 
when the mix was transparent, homogeneous, and stable, 
according to the method of Vrignaud et al.16
Preparation of rM-lNcs
RM-LNCs were prepared according to the method developed 
by Anton et al,14 corresponding to the PIT method described 
above, including several changes in the formulation. 
RM-LNCs were formed by introducing the RMs during the 
formulation process, just before the final dilution with water, 
when the system is known to be close to the micro-emulsion 
state. RM-LNCs were composed of 3.7% Oleic Plurol (w/w), 
5.6% Kolliphor HS-15 (w/w), 14.1% lipophilic Labrafac 
WL 1349 (w/w), 74.3% water (w/w), 1.9% NaCl and 0.5% 
dioctyl sodium sulfosuccinate (w/w).
Briefly, Oleic Plurol, Kolliphor HS-15, lipophilic 
Labrafac WL 1349, water, and NaCl were mixed by mag-
netic stirring. Three cycles of heating and cooling between 
30°C and 50°C were then carried out. During the last cycle, 
1 mL RMs was added at 43°C and the mixture stirred for 
40 seconds, followed by an irreversible shock induced 
by dilution with 2°C purified water. Magnetic stirring (at 
300 rpm) was then applied to the LNC suspension for 
5 minutes at room temperature. The structures of the RMs 
and RM-LNCs are represented in Figure 1.
characterization of rM-lNcs
The average hydrodynamic diameter associated with the 
polydispersity index (PDI) was measured by dynamic light 
scattering using a ZetasizerNano series DTS 1060 (Malvern 
Instruments S.A., Worcestershire, UK). The zeta potential 
was calculated from the electrophoretic mobility using the 
Smoluchowski equation. All measurements were performed 
in triplicate at 25°C after dilution with deionized water. 
To determine AP138 drug loading (DL), three samples of 
RM-LNCs were prepared by dissolution of an exact quantity 
of RM-LNC suspension in a methanol/brine solution (final 
ratio: 10/73/17), vortexed, subjected to ultrasound treatment, 
and centrifuged at 15,000 rpm for 5 minutes to eliminate 
the residual components of the RM-LNCs and excess NaCl. 
A 20 µL aliquot of each filtrate was injected onto an HPLC 
column. Chromatography was performed using a Waters® 717 
plus autosampler, Waters® 600 controller, and Waters® 2487 
Dual Absorbance Spectrometer (Waters S.A., Saint-Quen-
tin-en-Yvelynes, France) with a Symmetry shield® 250×4.60 
mm column (Waters, Milford, Ireland) and an ultraviolet 
detector set at 200 nm. The flow rate was set to 1.2 mL/min. 
The gradient was obtained by mixing phase A (water/0.1% 
TFA) and phase B (water/acetonitrile/TFA: 200/800/0.85). 
Initially, the mobile phase composition was 90% A. A linear 
gradient was then applied to reach a composition of 65% A 
after 5 minutes, 40% A after 14 minutes, and 100% after 14.1 
minutes, which was then maintained for 2 minutes before 
returning to the initial conditions. Quantification was achieved 
by comparing the peak area ratios of AP138 in the samples 
to a calibration curve obtained under the same experimental 
conditions. The AP138 peak had a retention time of 11.8 
minutes. Data collection and integration were performed using 
Empower® 3 software. Linearity was observed between 5 and 
100 µg/mL, with a correlation coefficient above 0.999. The 
detection and quantification limits were 1.2 and 3.5 µg/mL, 
respectively. The mean drug concentration (µg of AP138/g 
of RM-LNC dispersion) of each batch of RM-LNC disper-
sion and the SD were calculated for three samples. The ratio 
“experimental/theoretical AP138 concentration” (%) is an 
indicator of AP138 loss during AP138-loaded RM prepara-
tion. The experimental AP138 concentration corresponds to 
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Figure 1 structure of rM and rM-lNc.
Abbreviations: lNc, lipid nanocapsule; rM, reverse micelle.
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the total AP138 (free and encapsulated) in RM-LNC formula-
tions. The theoretical AP138 concentration depends on the 
exact mass of the AP138 weighed to prepare the AP138-RMs. 
Encapsulation efficiency (EE) was obtained by separating the 
free from encapsulated fractions of AP138 by dialysis (100 
kDa tubing, 24 hours in deionized water). The EE and DL 
were calculated using the following equations:
 
EE (%) = ×A
B
100
 
where A is the mass of encapsulated AP138 and B the total 
amount (mass) of AP138.
 
DL (%) = ×A
C
100
where C is the total weight of all components of the RM-
LNCs (the encapsulated AP138 and the mass of surfactants 
and oil used for the preparation of the RM-LNCs).
Determination of antibacterial activity
The antibacterial effect of AP138-RM-LNCs and AP138 
in solution was evaluated using two parameters: the MICs 
and time-kill assay. The strains used in this study were SA 
strain ATCC25923 and MRSA clinical strain 702E0196. For 
the determination of the MICs, bacterial suspensions with a 
turbidity equivalent to a McFarland 1.1 standard were pre-
pared in a 0.85% NaCl solution. The bacterial suspensions 
were then further diluted 100 times with brain heart infusion 
medium (bioMerieux, Marcy l’Etoile, France).
The MIC was determined via a broth microdilution method. 
Briefly, serial dilutions of AP138 solution or RM-LNCs were 
prepared in the wells of a 96-well plate, followed by the addition 
of bacterial suspensions. Bacterial suspensions without peptides 
were used as a control. After 24 hours of incubation at 37°C, 
the MIC values were determined as the lowest concentration 
of the antimicrobial that inhibited visible growth of the micro-
organism. A difference of more than one dilution is necessary 
to claim a significant difference between two samples.
The time-kill assay experiments were performed at a 
concentration of 2× MIC in brain heart infusion. The bacterial 
counts were measured 0, 3, 6, and 24 hours after incubation 
at 37°C. At each timepoint, 100 µL bacterial suspension was 
plated on Columbia agar supplemented with sheep’s blood 
(Oxoïd, Dardilly, France). After incubating the agar plates 
overnight at 37°C, the colonies were counted. Each bacterial 
count was performed in triplicate.
Protease degradation assay
One obvious method for bacteria to inactivate AMPs is to 
produce peptidases and proteases that could affect pep-
tide activity. Thus, preliminary tests of the stability of the 
peptides toward proteolysis were performed to establish 
whether the nanoformulations preserve peptide integrity. 
Trypsin was chosen as the model enzyme. Various ratios 
of trypsin:peptide:PBS were tested to reach the proteolytic 
concentration of trypsin for AP138. Free or encapsulated 
AP138 was incubated with a 1:2 (mass/mass) trypsin/peptide 
ratio at 37°C for up to 4 hours with gentle horizontal shak-
ing. Negative controls were performed by incubation of the 
peptides in PBS without peptidases at 37°C for up to 4 hours. 
Aliquots were taken after 10, 20, 30, and 45 minutes and 1, 
2, and 4 hours, diluted 10 times in methanol or 20 times in 
methanol:brine, and analyzed by reversed-phase HPLC to 
quantify the percentage of intact peptide.
release study
The release of AP138 was monitored by dialysis. One 
milliliter of the sample was placed in a Float-A-Lyzer® G2 
dialysis device with a 100 kDa molecular weight cut-off 
(Spectrum lab, Rancho Dominguez, CA, USA), prepared 
according to the manufacturer’s instructions, and incu-
bated in PBS pH 7.4 (European Pharmacopeia, 9th ed.) 
with gentle magnetic shaking at 100 rpm at 37°C ± 1°C. 
At appropriate intervals, 100 µL samples were withdrawn, 
assayed, and replaced by fresh buffer. The amount of 
AP138 in the release medium was determined by HPLC as 
described previously. All measurements were performed 
in triplicate.
Results and discussion
Physicochemical properties of lNc 
suspensions
RM-LNCs were successfully prepared and AP138 
encapsulated in the formulation. AP138-RM-LNCs had an 
average hydrodynamic diameter of 63 ± 1 nm and very nar-
row polydispersity (PDI=0.06), showing very low heteroge-
neity of the suspension (Table 1). AP138 encapsulation led to 
a slight size increase of the RM-LNCs and a lower negative 
zeta potential than that of blank RM-LNCs. This may be 
related to the positive charge of AP138 (Table 2). The EE 
reached 97.8% ± 1.2% at a DL of 0.151% ± 0.002%. This DL 
corresponds to a concentration of 285 µg of AP138/mL of 
LNC. The properties of AP138-RM were not tested, and the 
antimicrobial effect could be variable due to the instability of 
RMs in water. The advantage of new lipid-based carriers for 
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AMP delivery is the obtention of a well-controlled system 
with a repeatable antimicrobial effect.
antibacterial activity of formulations
The MIC values of the AP138 solution and AP138-RM-
LNCs against SA and MRSA are presented in Table 3. Both 
the AP138 solution and AP138-RM-LNCs had MICs of 
4 µg/mL against SA and 1–2 µg/mL against MRSA. There 
was no difference between the MICs of AP138 in solution and 
nano-encapsulated AP138. Non-loaded RM-LNCs showed 
no antibacterial activity at similar concentrations (data not 
shown). AP138-loaded RM-LNCs and the AP138 solution 
were evaluated by time-kill assay (Figure 2). The time-kill 
assays showed comparable results for the AP138 solution 
and AP138-RM-LNCs, as they were bactericidal from 18 to 
24 hours following the beginning of the experiments. Peptides 
may display sensitivity to manufacturing processing condi-
tions and excipients (ie, some surfactants, which can com-
promise peptide stability).23 Standard methods of nanovector 
preparation present several drawbacks, such as exposure of 
peptide to organic solvents, shear stress, and high or very low 
temperatures, which can modify the peptide morphology or 
denature it.24 Such chemical and physical modifications can 
lead to differences in bioperformance. However, the RM-
LNC formulation process preserved peptide activity.
The existence of SA mutants that are hypersensitive to 
host defense peptides, such as plectasin, has been described 
previously.25 Recently, the MICs of plectasin derivatives 
against 14 studied strains was determined by Umerska et al and 
the MICs of AP138 varied 16-fold (range 0.125–4 µg/mL).26 
This is in good agreement with previously reported data 
showing that the antibacterial spectrum of AP138 includes 
staphylococci such as MRSA.20 Garbacz et al reported that 
the MICs of AMPs for 215 isolates of SA from cystic fibro-
sis patients varied from 4 to 256 µg/mL.27 Wu et al showed 
that the MICs against SA ATCC 25923 of novel and control 
AMPs varied from 8 to 64 µg/mL.28 Compared to these 
results, the MIC of 1–4 µg/mL for AP138-RM-LNCs shows 
this formulation to be highly active against staphylococci. 
This study suggests that AP138-RM-LNCs may be a highly 
promising drug delivery system and acts a novel antibacterial 
agent against MRSA and SA. Moreover, lipid nanosystems 
could enhance bacterial uptake of AMPs by efficient fusion 
with infectious microbes. For example, drug-loaded lipo-
somes can readily fuse with bacterial membranes and release 
the drug directly into the bacteria.29 It is now important to 
determine whether LNCs improve bacterial penetration of 
AMPs. This could be accomplished by studying antimicrobial 
penetration in biofilms.30 Indeed, biofilms are aggregations 
of infectious bacteria which protect the infected area against 
antibiotics and other therapies – they are common in many 
types of infection and are difficult to penetrate.
release study
Approximately half of the dose of AP138 loaded into 
the RM-LNCs was released into PBS in the first 2 hours 
and up to 100% was released after 24 hours (Figure 3). 
Table 1 Properties of lNc
Formulation Size  
(nm)
PDI Zeta potential  
(mV)
Experimental/theoretical  
AP138 concentration (%)
DL (%) EE (%)
Blank rM-lNcs 57.9 ± 0.4 0.040 ± 0.003 -37.0 ± 1.0 – – –
aP138-lNcs 62.9 ± 0.6 0.059 ± 0.003 -25.6 ± 0.9 74.0 ± 1.0 0.151 ± 0.002 97.8 ± 1.2
Abbreviations: DL, drug loading; EE, encapsulation efficiency; LNC, lipid nanocapsule; PDI, polydispersity index; RM, reverse micelle.
Table 2 structure and properties of aP138
Sequence GFGCNGPWSEDDLRCHRHC 
KSIKGYRGGYCAKGGFVCKCY
Cyclic cys4–cys30, cys15–cys37,  
cys19–cys39
Molecular weight 4,460.3 Da
Theoretical isoelectric point 8.87
Number of amino acids 40
Number of cationic amino 
acids
7
Number of anionic amino 
acids
3
Net charge at ph 7 +4
Notes: The information was obtained from the manufacturer (PolyPeptide labo-
ratories, limhamn, sweden) and the table is adapted from Umerska a, cassisa V, 
Bastiat g, et al. synergistic interactions between antimicrobial peptides derived 
from plectasin and lipid nanocapsules containing monolaurin as a cosurfactant 
against Staphylococcus aureus. Int J Nanomedicine. 2017;12:5687–5699). copyright © 
2017 Umerska et al.26
Table 3 MIc of aP138-lNc (in µg of aP138/ml)
Sample name Staphylococcus 
aureus
Methicillin-resistant 
Staphylococcus aureus
aP138 solution 4 2
aP138-lNcs 4 1
Abbreviations: lNc, lipid nanocapsule; MIc, minimum inhibitory concentration.
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AP138-RM-LNCs displayed much better and more rapid 
release than other delivery systems for which protein release 
can take days.31 Indeed, the encapsulated peptide may inter-
act with the shell of the nanovector and its release could be 
affected, resulting in incomplete release.32 Drug release is an 
important parameter that affects the antibacterial activity of 
AMP-loaded LNCs,33 and release experiments can provide 
further insight into the in vitro antibacterial effect of the 
formulations. Boge et al demonstrated that the high affinity 
of AMPs to nanoparticles may retard their release, resulting 
in decreased amounts of free peptide available to exert their 
antibacterial activity.34 Indeed, if the drug is presented to 
bacteria in small quantities over a prolonged period, it may 
be more effectively neutralized by the microorganisms than 
if the same quantity is delivered all at once. Thus, the high 
affinity of the AMPs for nanovectors and prolonged release 
could result in the loss of antibacterial activity. However, 
this was not true for our delivery system. AMP release may 
occur rapidly after contact with the bacteria. However, if the 
amount of drug released results in a high drug concentration 
(higher than the MIC), prolonged release of the drug could 
be beneficial by allowing prolonged antibacterial action.
Figure 2 Time-kill curves of aP138 solution and aP138-lNcs against Staphylococcus aureus (A) and methicillin-resistant Staphylococcus aureus (B), twice the MIc of aP138 
solution.
Note: Mean ± sD (n=3).
Abbreviations: cFU, colony forming unit; lNc, lipid nanocapsule; MIc, minimum inhibitory concentration.
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Protease degradation assay
We first investigated the proteolytic stability of pure AP138 
using the four clinically relevant enzymes Pseudomonas 
aeruginosa elastase, human neutrophil elastase, SA V8, 
and SA aurolysine. After incubation for 6 hours at 37°C 
with the elastases, the samples were separated by size using 
Tris-Tricine gel electrophoresis to assess peptide degradation 
by the enzymes. AP138 was not degraded by any of the four 
tested enzymes (data not shown). However, because AP138 
contains basic residues (Arg, His, and Lys), as shown in 
Table 2, it can be cleaved by trypsin. Thus, we tested trypsin 
to evaluate the stability of AP138 against enzymatic degrada-
tion. As shown in Table 4, the properties of RM-LNCs were 
not modified by the incubation conditions, with or without 
trypsin. Their size, PDI, and zeta potential were unchanged 
after 2 hours of incubation.
AP138 in solution was not degraded in the absence of 
trypsin. Its concentration and that of AP138-RM-LNCs were 
not affected during incubation without trypsin (control), 
whereas they decreased during incubation with trypsin 
(Figure 4). In the presence of trypsin, the remaining AP138 
concentration, as a function of time, was higher for the AP138 
encapsulated in RM-LNCs. Indeed, the stability of AP138 in 
the RM-LNCs was significantly higher, for up to 120 minutes 
of incubation, than that of AP138 in solution, with the 
remaining ratio significantly higher for the AP138-RM-LNCs 
(P0.05, Student’s t-test). Thus, the encapsulation of AP138 
into RM-LNCs appears to limit its degradation. Antimicro-
bial activity may be impaired by susceptibility of the AMP 
to proteolytic degradation and undesirable interactions in the 
biological environment.35 Moreover, AMP proteolysis is a 
fairly common mechanism of bacterial resistance to AMPs36 
induced by the bacterial production of proteases.37 A few 
studies have demonstrated a direct correlation between the 
in vivo contribution of a protease to virulence and resistance 
to AMPs.38,39 As a consequence, it is essential to evaluate 
AP138 degradation by a model protease. Encapsulation is 
particularly useful for protecting sensitive peptides against 
clinically relevant enzymes. For example, the peptide LL37 
is degraded by infection-related enzymes from either bac-
teria (P. aeruginosa elastase [PE]) or human defense cells 
(leukocyte elastase [HNE]).40
Protease stability is a pivotal consideration in the devel-
opment of peptide-based drugs. Although AP138 appears 
to be stable in the presence of the four clinically relevant 
enzymes tested and in contact with SA (strain ATCC 
25923) and MRSA (clinical strain 702E0196), such infor-
mation on protease degradation is essential. Indeed, both 
SA and P. aeruginosa are known to develop resistance to 
AMP via mechanisms of proteolytic degradation.37 Many 
clinical strains of SA have been isolated that express vari-
ous proteases which can contribute to varying sensitivity 
and resistance. Garbacz et al determined that the MICs of 
AMPs for 215 isolates of SA from cystic fibrosis patients 
Figure 3 aP138 release.
Note: Mean ± sD (n=3).
Abbreviation: lNc, lipid nanocapsule.
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Table 4 Properties of lNcs after 2 hours of incubation at 37°c
Size 
(nm)
PDI Zeta potential 
(mV)
Before test 62.9 ± 0.6 0.059 ± 0.003 -25.6 ± 0.9
after test: control 64.7 ± 0.9 0.042 ± 0.006 -35.0 ± 2.2
after test: trypsin 65.5 ± 0.2 0.040 ± 0.007 -31.0 ± 1.0
Abbreviations: lNc, lipid nanocapsule; PDI, polydispersity index.
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can vary from 4 to 256 µg/mL.27 Encapsulating AP138 
into LNCs appears to be of benefit concerning protease 
degradation from further strains other than tested SA. It 
reduced proteolytic susceptibility, resulting in a higher 
antibacterial effect after exposure to enzyme than that of 
AMP in solution. Encapsulation of peptides in RM-LNCs 
may modify their bioavailability and protect them against 
an unfavorable environment.
The effective and potent action of peptides makes them the 
drugs of choice for the treatment of numerous diseases.41 Pep-
tides must be administrated through various routes to manifest 
their therapeutic effects. LNCs could be used as carriers for 
intravenous administration of peptides due to their small size and 
very good tolerance.42 Moreover, LNCs are a potential peptide 
drug carrier for oral delivery as they have been shown to be stable 
in gastrointestinal-simulated media,43 have demonstrated their 
ability to cross intestinal mucus,44 and show improved bioavail-
ability.45 Moreover, the free surface of AMP-encapsulating nano-
particulate systems could allow their decoration or modification 
to improve their delivery to intended sites.46 Peptide delivery still 
presents many challenges, but peptide-loaded RM-LNCs show 
great promise for various applications.
Conclusion
Here, we have demonstrated that AMPs can be successfully 
loaded into LNCs using RMs with high loading efficiency. 
The AP138-RM-LNCs showed preserved antimicrobial 
activity and protease resistance. Indeed, the activity of 
AP138-RM-LNCs did not appear to be markedly different for 
resistant strains, for example, between the reference strains 
of SA and MRSA.
Acknowledgments
The research leading to these results received funding from 
the European Union’s Seventh Framework Programme 
(FP7/2007–2013) under grant agreement No. 604182 (http://
ec.europa.eu.research). It was carried out within the Inno-
vative Nanoformulation of Antimicrobial Peptides to Treat 
Bacterial Infectious Diseases (FORMAMP) project.
Disclosure
The authors report no conflicts of interest in this work.
References
1. World Health Organization. Antimicrobial Resistance: Global Report on 
Surveillance 2014. Geneva: World Health Organization; 2014. Available 
from: http://www.who.int/drugresistance/documents/surveillancereport/
en/. Accessed October 25, 2018.
2. Patel S, Akhtar N. Antimicrobial peptides (AMPs): the quintessential 
‘offense and defense’ molecules are more than antimicrobials. Biomed 
Pharmacother. 2017;95:1276–1283.
3. Reddy KV, Yedery RD, Aranha C. Antimicrobial peptides: premises and 
promises. Int J Antimicrob Agents. 2004;24(6):536–547.
4. Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key 
components of the innate immune system. Crit Rev Biotechnol. 2012; 
32(2):143–171.
5. Eckert R. Road to clinical efficacy: challenges and novel strategies 
for antimicrobial peptide development. Future Microbiol. 2011;6(6): 
635–651.
6. Bi L, Yang L, Narsimhan G, Bhunia AK, Yao Y. Designing carbohydrate 
nanoparticles for prolonged efficacy of antimicrobial peptide. J Control 
Release. 2011;150(2):150–156.
Figure 4 aP138 degradation by trypsin.
Note: Mean ± sD (n=3).
Abbreviation: lNc, lipid nanocapsule.












       
5HP
DLQL
QJ
7LPHPLQXWHV
$3VROXWLRQWU\SVLQ
$3VROXWLRQFRQWURO
/1&$3WU\SVLQ
/1&$3FRQWURO
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
54
.1
10
.3
3 
on
 0
8-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7573
reverse micelle-lipid nanocapsules: a novel strategy for peptide delivery
 7. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted 
delivery of PSC-RANTES for HIV-1 prevention using biodegradable 
nanoparticles. Pharm Res. 2009;26(3):502–511.
 8. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial pep-
tides: an emerging category of therapeutic agents. Front Cell Infect 
Microbiol. 2016;6:194.
 9. Matougui N, Boge L, Groo AC, et al. Lipid-based nanoformulations 
for peptide delivery. Int J Pharm. 2016;502(1–2):80–97.
 10. Lange CF, Hancock RE, Samuel J, Finlay WH. In vitro aerosol delivery 
and regional airway surface liquid concentration of a liposomal cationic 
peptide. J Pharm Sci. 2001;90(10):1647–1657.
 11. Piotrowska U, Sobczak M, Oledzka E. Current state of a dual behaviour 
of antimicrobial peptides-therapeutic agents and promising delivery 
vectors. Chem Biol Drug Des. 2017;90(6):1079–1093.
 12. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase 
inversion-based process for the preparation of lipid nanocarriers. Pharm 
Res. 2002;19(6):875–880.
 13. Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit JP, Urban T. 
The adaptation of lipid nanocapsule formulations for blood administra-
tion in animals. Int J Pharm. 2009;379(2):266–269.
 14. Anton N, Mojzisova H, Porcher E, Benoit JP, Saulnier P. Reverse micelle-
loaded lipid nano-emulsions: new technology for nano-encapsulation 
of hydrophilic materials. Int J Pharm. 2010;398(1–2):204–209.
 15. Vrignaud S, Anton N, Gayet P, Benoit JP, Saulnier P. Reverse micelle-
loaded lipid nanocarriers: a novel drug delivery system for the sus-
tained release of doxorubicin hydrochloride. Eur J Pharm Biopharm. 
2011;79(1):197–204.
 16. Vrignaud S, Hureaux J, Wack S, Benoit JP, Saulnier P. Design, 
optimization and in vitro evaluation of reverse micelle-loaded 
lipid nanocarriers containing erlotinib hydrochloride. Int J Pharm. 
2012;436(1–2):194–200.
 17. Vonarbourg A, Passirani C, Desigaux L, et al. The encapsulation of 
DNA molecules within biomimetic lipid nanocapsules. Biomaterials. 
2009;30(18):3197–3204.
 18. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, 
targets the bacterial cell wall precursor Lipid II. Science. 2010; 
328(5982):1168–1172.
 19. Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide 
antibiotic with therapeutic potential from a saprophytic fungus. Nature. 
2005;437(7061):975–980.
 20. Lociuro S, Neve S, Kjærulf S, Nordkild P. AP138, a second generation 
plectasin, shows good bactericidal properties and long post-antibiotic 
effect. In: Final Programme; European Congress of Clinical Micro-
biology and Infectious Diseases; April 25-28, 2015; Copenhagen, 
Denmark.
 21. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused 
by community-acquired methicillin-resistant Staphylococcus aureus. 
Clin Infect Dis. 2008;46(Suppl 5):S368–S377.
 22. Venter H, Henningsen ML, Begg SL. Antimicrobial resistance in 
healthcare, agriculture and the environment: the biochemistry behind 
the headlines. Essays Biochem. 2017;61(1):1–10.
 23. Bak A, Leung D, Barrett SE, et al. Physicochemical and formulation 
developability assessment for therapeutic peptide delivery – a primer. 
AAPS J. 2015;17(1):144–155.
 24. Biswaro LS, da Costa Sousa MG, Rezende TMB, Dias SC, Franco OL. 
Antimicrobial peptides and nanotechnology, recent advances and chal-
lenges. Front Microbiol. 2018;9:855.
 25. Gottlieb CT, Thomsen LE, Ingmer H, Mygind PH, Kristensen HH, Gram L. 
Antimicrobial peptides effectively kill a broad spectrum of Listeria 
monocytogenes and Staphylococcus aureus strains independently 
of origin, sub-type, or virulence factor expression. BMC Microbiol. 
2008;8(1):205.
 26. Umerska A, Cassisa V, Bastiat G, et al. Synergistic interactions between 
antimicrobial peptides derived from plectasin and lipid nanocapsules 
containing monolaurin as a cosurfactant against Staphylococcus aureus. 
Int J Nanomedicine. 2017;12:5687–5699.
 27. Garbacz K, Kamysz W, Piechowicz L. Activity of antimicrobial 
peptides, alone or combined with conventional antibiotics, against 
Staphylococcus aureus isolated from the airways of cystic fibrosis 
patients. Virulence. 2017;8(1):94–100.
 28. Wu X, Wang Z, Li X, et al. In vitro and in vivo activities of antimicro-
bial peptides developed using an amino acid-based activity prediction 
method. Antimicrob Agents Chemother. 2014;58(9):5342–5349.
 29. Theerthagiri R, Achuthanandan JM, Krishnamurthy S. Antimicrobial 
magnetosomes for topical antimicrobial therapy. In: Nanobiomaterials 
in Antimicrobial Therapy: Applications of Nanobiomaterials. Norwich 
(NY): William Andrew Publishing; 2016:67–101.
 30. Sharma P, Rozenbaum RT, Woudstra W, et al. A constant depth film fer-
menter to grow microbial biofilms. Protoc Exch. Epub 2017 Mar 8.
 31. Corrigan OI, Li X. Quantifying drug release from PLGA nanoparticu-
lates. Eur J Pharm Sci. 2009;37(3–4):477–485.
 32. Mohammadi-Samani S, Taghipour B. PLGA micro and nanoparticles 
in delivery of peptides and proteins; problems and approaches. Pharm 
Dev Technol. 2015;20(4):385–393.
 33. Nehme H, Saulnier P, Ramadan AA, et al. Antibacterial activity of 
antipsychotic agents, their association with lipid nanocapsules and its 
impact on the properties of the nanocarriers and on antibacterial activity. 
Becker K, ed. PLoS One. 2018;13(1):e0189950.
 34. Boge L, Umerska A, Matougui N, et al. Cubosomes post-loaded with 
antimicrobial peptides: characterization, bactericidal effect and prote-
olytic stability. Int J Pharm. 2017;526(1–2):400–412.
 35. Brandelli A. Nanostructures as promising tools for delivery of antimi-
crobial peptides. Mini Rev Med Chem. 2012;12(8):731–741.
 36. Andersson DI, Hughes D, Kubicek-Sutherland JZ. Mechanisms and 
consequences of bacterial resistance to antimicrobial peptides. Drug 
Resist Updat. 2016;26:43–57.
 37. Nizet V. Antimicrobial peptide resistance mechanisms of human bacte-
rial pathogens. Curr Issues Mol Biol. 2006;8(1):11–26.
 38. Sieprawska-Lupa M, Mydel P, Krawczyk K, et al. Degradation of 
human antimicrobial peptide LL-37 by Staphylococcus aureus-derived 
proteinases. Antimicrob Agents Chemother. 2004;48(12):4673–4679.
 39. Belas R, Manos J, Suvanasuthi R. Proteus mirabilis ZapA metallopro-
tease degrades a broad spectrum of substrates, including antimicrobial 
peptides. Infect Immun. 2004;72(9):5159–5167.
 40. Braun K, Pochert A, Lindén M, et al. Membrane interactions of 
mesoporous silica nanoparticles as carriers of antimicrobial peptides. 
J Colloid Interface Sci. 2016;475:161–170.
 41. Jain A, Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. Peptide and 
protein delivery using new drug delivery systems. Crit Rev Ther Drug 
Carrier Syst. 2013;30(4):293–329.
 42. Hureaux J, Lagarce F, Gagnadoux F, et al. Toxicological study and 
efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. 
administration in mice. Pharm Res. 2010;27(3):421–430.
 43. Roger E, Lagarce F, Benoit JP. The gastrointestinal stability of lipid 
nanocapsules. Int J Pharm. 2009;379(2):260–265.
 44. Groo AC, Saulnier P, Gimel JC, et al. Fate of paclitaxel lipid nanocap-
sules in intestinal mucus in view of their oral delivery. Int J Nanomedi-
cine. 2013;8(1):4291.
 45. Groo AC, Bossiere M, Trichard L, Legras P, Benoit JP, Lagarce F. 
In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intra-
venous and oral administration on resistant tumor. Nanomedicine. 
2015;10(4):589–601.
 46. Liu C, Kou Y, Zhang X, Cheng H, Chen X, Mao S. Strategies and 
industrial perspectives to improve oral absorption of biological mac-
romolecules. Expert Opin Drug Deliv. 2018;15(3):223–233.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
54
.1
10
.3
3 
on
 0
8-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
7574
groo et al
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
54
.1
10
.3
3 
on
 0
8-
Ja
n-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
